ReAlta’s CEO Dr. Ulrich Thienel and CFO John Rickman are attending the 22nd Annual Needham & Company Virtual Healthcare Conference April 17-20th, where they are meeting with investors to discuss our latest program developments, including an upcoming Phase 2 clinical trial for hypoxic-ischemic encephalopathy (HIE), and other life-threatening rare diseases. Dr. Thienel will be presenting an overview of the company’s platform technology and the recently completed proof of mechanism study at 10:15am EST on Monday, April 17.
#biotech #raredisease #needham
Dr. Neel Krishna and Dr. Katherine LaVallee, DVM did an outstanding job leading tours of our lab and offices last...Read More
We want to thank Rep. Elaine Luria and Norfolk Mayor Dr. Kenneth Alexander for helping us celebrate the official opening...Read More
ReAlta Life Sciences is officially part of Team Hope! We are extending our gratitude to the Hope for HIE team...Read More